Mannatech (NASDAQ:MTEX) and STADA Arzneimit/AKT o.N. (OTCMKTS:STDAF) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability.
Risk and Volatility
Mannatech has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Comparatively, STADA Arzneimit/AKT o.N. has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.
This table compares Mannatech and STADA Arzneimit/AKT o.N.’s net margins, return on equity and return on assets.
Institutional & Insider Ownership
16.0% of Mannatech shares are held by institutional investors. 24.7% of Mannatech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Mannatech pays an annual dividend of $2.00 per share and has a dividend yield of 10.4%. STADA Arzneimit/AKT o.N. does not pay a dividend. Mannatech has raised its dividend for 2 consecutive years.
Valuation & Earnings
This table compares Mannatech and STADA Arzneimit/AKT o.N.’s top-line revenue, earnings per share (EPS) and valuation.
STADA Arzneimit/AKT o.N. has higher revenue and earnings than Mannatech.
This is a summary of current ratings and recommmendations for Mannatech and STADA Arzneimit/AKT o.N., as reported by MarketBeat.
Mannatech Company Profile
Mannatech, Incorporated provides wellness solutions. The company develops, markets, and sells nutritional supplements, topical, skin care and anti-aging products, and weight-management products. It markets its products through network marketing channels in the Americas, Europe/the Middle East/Africa, and the Asia/Pacific. The company was founded in 1993 and is headquartered in Coppell, Texas.
STADA Arzneimit/AKT o.N. Company Profile
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux. The Branded Products segment offers APO-Go a Parkinson's medicine; Grippostad a cold medicine; Aqualor for rhinitis/sore throat; Snup for rhinitis; and Vitaprost for prostate disease indications. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH.